Trials / Unknown
UnknownNCT01079013
Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
Phase II Trial of Fludarabine Combined With Intravenous Treosulfan and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Lymphatic Malignancies
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Sheba Medical Center · Other Government
- Sex
- All
- Age
- 18 Years – 68 Years
- Healthy volunteers
- Not accepted
Summary
The study hypotheses is that the introduction of dose escalated treosulfan, in substitution to busulfan or melphalan, will reduce toxicity after allogeneic transplantation while improving disease eradication in patients with lymphoid malignancies not eligible for standard transplantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | treosulfan | 12 g/m2 x 3 days |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2018-04-01
- Completion
- 2018-04-01
- First posted
- 2010-03-02
- Last updated
- 2016-04-20
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01079013. Inclusion in this directory is not an endorsement.